investing.comOct 30$MMSI

Canaccord raises Merit Medical stock price target on Q3 beat

Canaccord raised its price target on Merit Medical Systems (MMSI) to $121 from $94, maintaining a Buy rating. The company reported Q3 revenue of $416.2M, up 8% YoY, and EPS of $1.12, up 22% YoY, both beating estimates. MMSI raised its fiscal 2026 EPS guidance to $4.33-$4.37. The stock is up 37% over six months and near its 52-week high.

Original reporting

investing.com

Published Oct 30, 2026, 10:36 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 30, 2026, 11:04 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$MMSI

Bullish

high confidence

Mentioned

$MMSI

Relevance

7/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$MMSIBullishMed

Why it matters

The earnings beat and raised guidance underpin the analyst's higher price target, indicating a bullish outlook.

Market read

Earnings beat and upgraded guidance for a mid‑cap med‑tech firm provide a clear catalyst for short‑term price appreciation.

What to watch

Potential cost pressures and competitive dynamics in the med‑tech space.

Relevance 7/10Novelty 7/10Timing: post‑earnings release

Background

Merit Medical reported Q3 revenue of $416.2 M (+8% YoY) and EPS of $1.12, beating estimates. Guidance for FY 2026 was raised.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$MMSIBullishHigh confidence

Context

Canaccord raised its price target on Merit Medical to $121 and highlighted Q3 earnings beat and raised FY guidance.

Expected impact

likely upward pressure as investors price in higher earnings expectations

Evidence & confidence

The price target increase to $121 from $94 reflects a material re‑rating; combined with better‑than‑expected earnings and higher guidance, the market may bid the stock higher.

Market effects

Sector

Positive for the medical‑device sector as Merit Medical's beat may lift peers.

Regional

U.S. healthcare equities could see modest gains.

Global

Limited to U.S. and global med‑tech investors.

Counterpoint

What could challenge this read

The stock may already be priced for growth; further upside could be limited.

Key entities

company
Merit Medical Systems, Inc.
Medical‑device manufacturer (NASDAQ:MMSI).
analyst
Canaccord Genuity
Equity research firm that raised the price target.

Read at source ← All news

$MMSIMedAI 8/10

Merit Medical Systems, Inc. (MMSI) Reports 92.7% Six-Month TLPP in AVF Cohort

Merit Medical reported 6-month data from 237 AVF patients in 9 countries, showing 92.7% TLPP and 76.7% ACPP, compared to prior trial rates of 89.8% and 72.8%. The company aims to expand evidence with longer follow-up and additional registries.

tradingview.comNov 5

$MMSIMedAI 8/10

At six months, 92.7% of patients needed no repeat procedure for the treated dialysis-access blockage.

Merit Medical Systems (MMSI) reported 6-month data from the WRAP Global registry, showing 92.7% target lesion primary patency and 76.7% access circuit primary patency for its WRAPSODY CIE device in arteriovenous fistula patients. Results exceeded those from prior trials, according to the company. The device is FDA-approved and commercially available in the U.S., EU, and other regions.

stocktitan.netNov 5

$MMSIHighAI 8/10

MMSI Q3 deep dive: balanced organic growth, new acquisitions, and margin improvement

MMSI reported Q3 revenue of $416.2M, beating estimates by 1.5%, and raised full-year guidance to $1.64B. Adjusted EPS was $1.12, a 7.8% beat, with guidance increased to $4.35. Operating margin improved to 14.1% from 11.1%. Growth was driven by foundational and therapeutic segments, with strong demand in oncology and endoscopy. The company acquired Solo Pace to expand its Cardiac Therapies platform.

finance.yahoo.comNov 1

$MMSIHigh

Merit Acquires Solo Pace For $45 Mln; Shares Down

Merit Medical Systems (MMSI) acquired Solo Pace, Inc. for $45 million, adding its pacing systems to Merit's Cardiac Therapies. The deal expands Merit's structural heart portfolio. Shares fell 6.84% to $87.00.

rttnews.comOct 30

$MMSIMed

Needham raises Merit Medical stock price target on strong results

Needham raised its price target for Merit Medical Systems (MMSI) to $106 from $101, maintaining a Buy rating. The company's Q3 2026 revenue and EPS beat estimates, with organic revenue growth of 8.9% YoY. Management raised full-year 2026 guidance. MMSI also announced a $45M acquisition of Solo Pace. Shares trade near a 52-week high at $93.39, with InvestingPro suggesting undervaluation.

investing.comOct 30